PL3578266T3 - Formulacja octanu abirateronu - Google Patents

Formulacja octanu abirateronu

Info

Publication number
PL3578266T3
PL3578266T3 PL19173089.4T PL19173089T PL3578266T3 PL 3578266 T3 PL3578266 T3 PL 3578266T3 PL 19173089 T PL19173089 T PL 19173089T PL 3578266 T3 PL3578266 T3 PL 3578266T3
Authority
PL
Poland
Prior art keywords
acetate formulation
abirateron
abirateron acetate
formulation
acetate
Prior art date
Application number
PL19173089.4T
Other languages
English (en)
Inventor
William H. Bosch
Marck Norret
Paul NEMETH
Matt Callahan
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of PL3578266T3 publication Critical patent/PL3578266T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B02CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02CCRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C19/00Other disintegrating devices or methods
    • B02C19/16Mills provided with vibrators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19173089.4T 2013-03-15 2014-03-17 Formulacja octanu abirateronu PL3578266T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789141P 2013-03-15 2013-03-15
US201361883941P 2013-09-27 2013-09-27

Publications (1)

Publication Number Publication Date
PL3578266T3 true PL3578266T3 (pl) 2024-10-21

Family

ID=51538105

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19173089.4T PL3578266T3 (pl) 2013-03-15 2014-03-17 Formulacja octanu abirateronu
PL14765788T PL2969227T3 (pl) 2013-03-15 2014-03-17 Formulacja octanu abirateronu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14765788T PL2969227T3 (pl) 2013-03-15 2014-03-17 Formulacja octanu abirateronu

Country Status (20)

Country Link
US (3) US20140287039A1 (pl)
EP (2) EP2969227B1 (pl)
JP (4) JP2016514707A (pl)
KR (3) KR20160023641A (pl)
CN (2) CN110604721B (pl)
AU (2) AU2014232508C1 (pl)
BR (1) BR112015023629A8 (pl)
CA (1) CA2907415C (pl)
CL (1) CL2015002787A1 (pl)
ES (2) ES2741800T3 (pl)
HK (1) HK1219457A1 (pl)
IL (1) IL241612B (pl)
MX (1) MX2015013247A (pl)
NZ (1) NZ712350A (pl)
PL (2) PL3578266T3 (pl)
RU (1) RU2732136C2 (pl)
SG (2) SG10201709400VA (pl)
TW (2) TWI731321B (pl)
WO (1) WO2014145813A1 (pl)
ZA (1) ZA201507209B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771722B1 (en) 2011-10-28 2018-08-22 GX Technology Canada Ltd. Steerable fairing string
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US10045998B2 (en) 2013-12-12 2018-08-14 Basf Se Solid form of abiraterone acetate
IN2014MU00303A (pl) * 2014-01-28 2015-09-11 Cipla Ltd
EP3193857A4 (en) * 2014-09-18 2018-04-11 Iceutica Inc. Abiraterone acetate formulation and methods of use
CN105616364B (zh) * 2014-11-07 2018-11-02 深圳万乐药业有限公司 醋酸阿比特龙片及其制备方法
WO2016090098A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Anticancer compositions
ES3019912T3 (en) 2014-12-05 2025-05-21 Aragon Pharmaceuticals Inc Anticancer compositions
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
ES2863500T3 (es) * 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
WO2017136617A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
EP3764129A1 (en) 2016-02-16 2021-01-13 GX Technology Canada Ltd. Ribbon foil depressor
TN2018000366A1 (en) * 2016-06-03 2020-06-15 Aragon Pharmaceuticals Inc Anticancer compositions.
KR102771163B1 (ko) 2017-04-07 2025-02-25 엠에이에이 래보러토리스, 인코포레이티드 치료제의 용해도 및 생체이용률을 향상시키는 방법
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
MA50189A (fr) * 2017-09-22 2021-05-19 Dispersol Technologies Llc Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
US20210008081A1 (en) * 2018-03-29 2021-01-14 Leiutis Pharmaceuticals Pvt, Ltd Oral liquid formulations of abiraterone
EP3826770B1 (en) * 2018-07-24 2024-08-28 Camx Power, L.L.C. Dry milling additive and process
CN112788950A (zh) * 2018-07-31 2021-05-11 微生物公司 用于治疗伤口的铋-硫醇组合物和方法
WO2020028558A1 (en) 2018-07-31 2020-02-06 Microbion Corporation Bismuth-thiol compositions and methods of use
HU231297B1 (hu) * 2018-07-31 2022-09-28 Richter Gedeon Nyrt Stabil gyógyszerkészítmények és eljárás az előállításukra
CN113382922B (zh) 2018-10-09 2024-07-19 Gx技术加拿大有限公司 用于拖曳式海洋阵列的模块化翼型系统
WO2020151633A1 (en) * 2019-01-25 2020-07-30 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
JP2022525425A (ja) * 2019-03-18 2022-05-13 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー アビラテロン-環状オリゴマー薬学的製剤ならびにその形成方法および投与方法
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7716396B2 (ja) * 2019-10-22 2025-07-31 アルビナス・オペレーションズ・インコーポレイテッド 前立腺癌を治療する方法
CN113133983B (zh) * 2020-01-20 2023-12-12 鲁南制药集团股份有限公司 一种治疗前列腺癌的药物组合物
IL297338A (en) * 2020-04-16 2022-12-01 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
US12103056B2 (en) 2020-05-07 2024-10-01 Nanchang University Organic waste collection apparatus and method
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN112933053B (zh) * 2021-01-29 2022-11-25 中国药科大学 一种醋酸阿比特龙的纳米晶体及其制剂和制备方法
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
US11801252B2 (en) * 2021-03-05 2023-10-31 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
KR20240010280A (ko) 2022-07-15 2024-01-23 한미약품 주식회사 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 약제학적 조성물
WO2025163665A1 (en) * 2024-01-29 2025-08-07 Dr. Reddy’S Laboratories Limited Stable pharmaceutical compositions of abiraterone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
BRPI0713053A2 (pt) * 2006-06-30 2012-07-17 Iceutica Pty Ltd métodos para a preparação de compostos biologicamente ativos na forma nanoparticulada
EP3804730A1 (en) * 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
US20090088424A1 (en) * 2007-08-17 2009-04-02 Ilan Zalit Methods and compositions for controlling the bioavailability of poorly soluble drugs
AU2010239081C1 (en) * 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
CA2759109A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
SG10201401705VA (en) * 2009-04-24 2014-08-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
JP6222924B2 (ja) * 2009-04-24 2017-11-01 イシューティカ ピーティーワイ リミテッド ジクロフェナクの新規製剤
PL2696848T3 (pl) * 2011-04-15 2020-12-28 Janssen Pharmaceutica N.V. Liofilizowane nanozawiesiny leków
BR112014001440A2 (pt) * 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
GB201207886D0 (en) 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009436A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102743393A (zh) 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
WO2014083512A1 (en) * 2012-11-28 2014-06-05 Dr. Reddy's Laboratories Limited Process for preparation of abiraterone acetate

Also Published As

Publication number Publication date
AU2018241103B2 (en) 2020-08-13
ES2986853T3 (es) 2024-11-13
CL2015002787A1 (es) 2016-05-13
TWI731321B (zh) 2021-06-21
KR20190141270A (ko) 2019-12-23
TW201943408A (zh) 2019-11-16
EP3578266A1 (en) 2019-12-11
WO2014145813A1 (en) 2014-09-18
JP7320485B2 (ja) 2023-08-03
JP2021008521A (ja) 2021-01-28
IL241612B (en) 2020-03-31
KR20160023641A (ko) 2016-03-03
US20140287039A1 (en) 2014-09-25
EP3578266B1 (en) 2024-06-19
AU2014232508C1 (en) 2023-01-19
AU2014232508B2 (en) 2018-07-12
JP2018135351A (ja) 2018-08-30
BR112015023629A2 (pt) 2017-07-18
EP2969227A1 (en) 2016-01-20
CN105246598B (zh) 2019-09-13
CN110604721B (zh) 2022-02-08
JP2016514707A (ja) 2016-05-23
SG10201709400VA (en) 2018-01-30
TW201513896A (zh) 2015-04-16
CA2907415A1 (en) 2014-09-18
KR20180021932A (ko) 2018-03-05
EP2969227A4 (en) 2016-12-07
CN110604721A (zh) 2019-12-24
BR112015023629A8 (pt) 2023-04-11
EP2969227B1 (en) 2019-05-08
HK1219457A1 (zh) 2017-04-07
US20170354665A1 (en) 2017-12-14
KR102121404B1 (ko) 2020-06-11
NZ712350A (en) 2020-08-28
JP2023103410A (ja) 2023-07-26
PL2969227T3 (pl) 2019-12-31
CN105246598A (zh) 2016-01-13
JP7752150B2 (ja) 2025-10-09
AU2018241103A1 (en) 2018-10-25
MX2015013247A (es) 2016-11-25
HK1220162A1 (en) 2017-04-28
SG11201507681PA (en) 2015-10-29
RU2732136C2 (ru) 2020-09-11
US20160067265A1 (en) 2016-03-10
AU2014232508A1 (en) 2015-10-08
TWI686212B (zh) 2020-03-01
RU2015144285A (ru) 2017-04-24
ES2741800T3 (es) 2020-02-12
ZA201507209B (en) 2016-12-21
CA2907415C (en) 2022-04-05

Similar Documents

Publication Publication Date Title
NL301171I1 (nl) Tigolaner
NO2021038I1 (no) lumasiran
PL3578266T3 (pl) Formulacja octanu abirateronu
EP3065716C0 (en) FORMULATIONS
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
HUE037097T2 (hu) Hõszigetelõpanel
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
PL2945641T3 (pl) Cykloalkinowe pochodne sacharydów
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
NL301170I1 (nl) Somatrogon
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
HUE050917T2 (hu) Hidrokortizon-tartalmú készítmény
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
FI10343U1 (fi) Mittateippi